1. Home
  2. GCTK vs OGEN Comparison

GCTK vs OGEN Comparison

Compare GCTK & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GCTK
  • OGEN
  • Stock Information
  • Founded
  • GCTK 2001
  • OGEN 1996
  • Country
  • GCTK United States
  • OGEN United States
  • Employees
  • GCTK N/A
  • OGEN N/A
  • Industry
  • GCTK Medical/Dental Instruments
  • OGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • GCTK Health Care
  • OGEN Health Care
  • Exchange
  • GCTK Nasdaq
  • OGEN Nasdaq
  • Market Cap
  • GCTK 5.1M
  • OGEN 4.6M
  • IPO Year
  • GCTK N/A
  • OGEN N/A
  • Fundamental
  • Price
  • GCTK $0.19
  • OGEN $0.21
  • Analyst Decision
  • GCTK
  • OGEN
  • Analyst Count
  • GCTK 0
  • OGEN 0
  • Target Price
  • GCTK N/A
  • OGEN N/A
  • AVG Volume (30 Days)
  • GCTK 8.8M
  • OGEN 340.9K
  • Earning Date
  • GCTK 05-14-2025
  • OGEN 05-14-2025
  • Dividend Yield
  • GCTK N/A
  • OGEN N/A
  • EPS Growth
  • GCTK N/A
  • OGEN N/A
  • EPS
  • GCTK N/A
  • OGEN N/A
  • Revenue
  • GCTK N/A
  • OGEN N/A
  • Revenue This Year
  • GCTK N/A
  • OGEN N/A
  • Revenue Next Year
  • GCTK N/A
  • OGEN N/A
  • P/E Ratio
  • GCTK N/A
  • OGEN N/A
  • Revenue Growth
  • GCTK N/A
  • OGEN N/A
  • 52 Week Low
  • GCTK $0.16
  • OGEN $0.19
  • 52 Week High
  • GCTK $99.00
  • OGEN $3.43
  • Technical
  • Relative Strength Index (RSI)
  • GCTK 28.80
  • OGEN 26.93
  • Support Level
  • GCTK $0.16
  • OGEN $0.19
  • Resistance Level
  • GCTK $0.24
  • OGEN $0.22
  • Average True Range (ATR)
  • GCTK 0.06
  • OGEN 0.02
  • MACD
  • GCTK 0.04
  • OGEN -0.01
  • Stochastic Oscillator
  • GCTK 5.84
  • OGEN 15.11

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Share on Social Networks: